



Date: February 06, 2025

To, Dept. of Corporate Services, **BSE Limited** 1st Floor, P.J. Towers, Dalal Street, Fort, Mumbai: 400001. Dear Sir,

Sub.: Reply to the clarification sought by the stock exchange with reference to the significant movement in the price of the securities of the Company.

Ref: CLINITECH LABORATORY LIMITED (CTLLAB) Scrip Code: 544220.

Respected Sir,

In context to the above and in response to your email seeking clarification from the Company regarding significant movement in price, we hereby clarify that the company is not aware of any undisclosed material information/disclosure which is price sensitive and that may be impacting the share price movement.

Further, we wish to inform you that we are fully compliant with all the regulatory requirements regarding disclosing price sensitive information to the various stakeholders and have been duly complying with Regulation 30 of SEBI (Listing obligation and Disclosure Requirement Regulation 2015 and will continue to keep the exchange informed of any material developments as they may occur from time to time.

Kindly take the same on record and acknowledge the receipt

Thanking you,

Yours faithfully, **For CLINITECH LABORATORY LIMITED** (formerly known as Clinitech Laboratory Private Limited)

Jagdish Umakant Nayak Chairman and Managing Director DIN:00646672